RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016

RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016
Published Jun 30, 2016
58 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016, provides in depth analysis on RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1)
- The report reviews RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued p

  
Source:
Document ID
GMDHC0203TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Overview71
Therapeutics Development84
  RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Products under Development by Stage of Development81
  RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Products under Development by Therapy Area91
  RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Products under Development by Indication102
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Products under Development by Companies144
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Therapeutics Assessment185
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration202
  Assessment by Molecule Type221
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Companies Involved in Therapeutics Development236
  ArQule, Inc.231
  AstraZeneca Plc241
  Cipher Pharmaceuticals Inc.251
  Merck &Co., Inc.262
  Novartis AG281
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Drug Profiles2914
  ARQ-092 Drug Profile293
  AZD-5363 Drug Profile322
  ISC-4 Drug Profile341
  JRP-890 Drug Profile351
  MK-2206 Drug Profile363
  MK-2206 + selumetinib sulfate Drug Profile391
  trametinib dimethyl sulfoxide + uprosertib Drug Profile402
  uprosertib Drug Profile421
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Dormant Projects433
RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) Featured News &Press Releases4611
  Jan 28, 2016: ArQule Provides Update on ARQ 092461
  Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092462
  Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics481
  Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics491
  Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology491
  Sep 28, 2015: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference501
  Nov 13, 2014: ArQule Announces Data Presentations on ARQ 092 at 26th EORTC-NCI-AACR Symposium511
  Nov 11, 2014: ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome521
  Oct 21, 2013: New Drug Combinations May Benefit Patients With Pancreatic Cancer521
  Apr 09, 2013: ArQule s New AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase I Trial531
  Apr 07, 2013: AstraZeneca's AKT Inhibitor AZD5363 Well Tolerated, Yieldes Partial Response In Patients With Advanced Solid Tumors, Phase I Study Finds541
  Nov 10, 2011: Daiichi Sankyo To License ARQ 092 From ArQule, The First New Compound Resulting From The Companies Joint AKIP Research Collaboration551
  Apr 12, 2011: Astex Announces Commencement Of Phase I Study For AZD5363 In Anti-Cancer Collaboration With AstraZeneca561
  Jun 01, 2009: AstraZeneca and Merck &Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen561
Appendix572
  Methodology571
  Coverage571
  Secondary Research571
  Primary Research571
  Expert Panel Validation571
  Contact Us571
  Disclaimer581

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/RAC-Gamma-Serine-Threonine-Protein-Kinase-Akt-3-or-Protein-Kinase-Akt-3-or-Protein-Kinase-B-Gamma-or-RAC-PK-Gamma-or-STK-2-or-EC-2-7-11-1-Pipeline-Review-H1-2016-2088-16096>
  
APA:
Global Markets Direct - Market Research. (2016). RAC-Gamma Serine/Threonine-Protein Kinase (Akt-3 or Protein Kinase Akt-3 or Protein Kinase B Gamma or RAC-PK-Gamma or STK-2 or EC 2.7.11.1) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/RAC-Gamma-Serine-Threonine-Protein-Kinase-Akt-3-or-Protein-Kinase-Akt-3-or-Protein-Kinase-B-Gamma-or-RAC-PK-Gamma-or-STK-2-or-EC-2-7-11-1-Pipeline-Review-H1-2016-2088-16096>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.